ENTITY
Pharmaessentia Corp

Pharmaessentia Corp (6446 TT)

124
Analysis
Health Care • Taiwan
PharmaEssentia Corporation develops and distributes therapeutic products for treatment in human disease. The Company develops drugs to treat hepatitis, chronic myeloid leukemia (CML), essential thrombocythemia (ET), myeloid fibrosis (MF), polycythemia vera (PV), hepatitis and cancer.
more
bullish•Pharmaessentia Corp
•04 Sep 2026 16:23

Quiddity T50/100/TDIV Sep26 Results: All Changes in Line with Expectations Except for One

We expected King Yuan Electronics Co, Ltd. (2449 TT) to get deleted from T50. However, the next-in-line potential DEL Alchip Technologies (3661 TT)...

Share
bullish•Pharmaessentia Corp
•24 Aug 2026 22:55

Quiddity Leaderboard T50/​​​100 Sep26: Final Expectations

We expect PharmaEssentia Corp (6446 TT) to replace King Yuan Electronics Co, Ltd. (2449 TT) in the T50 index in September 2026.

Share
bullish•Pharmaessentia Corp
•21 Aug 2026 08:30

Pharmaessentia Corp (6446 TT): Stellar 2Q Performance; Eye on Imminent Label Expansion of Besremi

Pharmaessentia reported 2Q26 results, with accelerated double-digit revenue growth and significant improvement in profitability. FDA action date...

Logo
110 Views
Share
bearish•Pharmaessentia Corp
•11 Aug 2026 14:49

Pharmaessentia Corp (6446 TT): Synthetic Expert Call Transcript (11 Aug 2026)

US Commercial Growth & GTN Quality: The recent surge in US revenue—bringing consolidated year-to-date revenue to NT$11.98 billion as of June...

Share
bullish•Pharmaessentia Corp
•11 Aug 2026 08:13

Primer: Pharmaessentia Corp (6446 TT) - Aug 2026

PharmaEssentia is experiencing explosive growth driven by its core product, Besremi®, a novel, long-acting interferon for the treatment of...

Share
x